Clinical Trials Logo

Alcohol Abuse clinical trials

View clinical trials related to Alcohol Abuse.

Filter by:

NCT ID: NCT05942352 Recruiting - Alcohol Abuse Clinical Trials

Clinical Study of Ligustrazine in Treating Alcohol Addiction

Start date: July 28, 2023
Phase: Phase 4
Study type: Interventional

Alcohol consumption is one of the most important risk factors for chronic non-communicable diseases in the population, and it is also the main cause of death from cancer, cardiovascular disease and lung disease, causing serious health, economic and social problems. The current alcohol-abstinence drugs have limited therapeutic effects and still present a high relapse rate. It is an urgent need to develop effective drugs for the treatment of alcohol addiction. The multimodal mechanism of action of ligustrazine in the central nervous system indicates that ligustrazine is expected to be developed as a potential therapeutic drug for alcohol addiction. Our study investigated the therapeutic effect of ligustrazine on subjects with alcohol addiction and the mechanism of multimodal brain imaging by administering ligustrazine, in order to develop new targeted drugs for alcohol treatment and provide more effective diagnosis and treatment methods for clinical treatment.

NCT ID: NCT05895643 Recruiting - Clinical trials for Alcohol Use Disorder

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

SEMALCO
Start date: June 13, 2023
Phase: Phase 2
Study type: Interventional

This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of the GLP-1 receptor agonist semaglutide s.c. vs placebo on alcohol consumption in 108 patients diagnosed with alcohol use disorder and comorbid obesity (BMI>30 kg/m2). Patients will be treated for 26 weeks with semaglutide subcutaneously (s.c.) once weekly or placebo. The medication will be provided as a supplement to standardised cognitive behavioural therapy. A subgroup of the patients will have two brain scans (Magnetic Resonance Spectroscopy (MRS) and functional Magnetic Resonance Imaging (fMRI)) conducted in one scan session at week 0 and 26. The primary endpoint is the percentage-point reduction in total number of heavy drinking days, defined as days with an excess intake of 48/60 grams of alcohol per day (women and men, respectively) from baseline to follow-up after 26 weeks of treatment, measured by the timeline followback (TLFB) method.

NCT ID: NCT05855031 Recruiting - Clinical trials for Alcohol Use Disorder

The Liver Care Trial

Start date: May 8, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy of screening for liver disease with liver stiffness measurement on abstinence or light consumption after 6 months in individuals who are receiving treatment for alcohol use disorder and without a history of liver disease. The investigators will conduct a randomized controlled trial with concealed allocation comparing A) an invitation to a liver stiffness measurement, blood sampling and leaflet on alcohol-related disease (intervention) with B) an invitation to blood sampling (control). The primary outcome is 'abstinence or light consumption' (≤ 10 units/week) throughout the last months, and assessed 6 months after randomization.

NCT ID: NCT05837611 Recruiting - Alcohol Abuse Clinical Trials

Deposit Contracts to Increase Accessibility of a Contingency Management Intervention to Reduce Problematic Drinking

Start date: June 10, 2022
Phase: N/A
Study type: Interventional

This study will examine the effects of an incentive-based intervention (for reducing alcohol use) that would be sustainable, easily accessible intervention using remote alcohol monitoring and deposit contracts, targeting individuals who would not be reached by more traditional forms of treatment due to barriers such as time constraints, attitudes, and stigma.

NCT ID: NCT05827822 Recruiting - Clinical trials for Alcohol Use Disorder

Effectiveness of a WeChat-based Alcohol Consumption Intervention Mini-program ("Sober Time ACT") in China

Start date: March 9, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to explore whether "Sober Time ACT", a digital intervention tool for alcohol use developed based on wechat mini program, is effective in improving risky alcohol use among Chinese local drinkers.

NCT ID: NCT05756790 Active, not recruiting - HIV/AIDS Clinical Trials

Couple-Based Motivational Interviewing With Mobile Breathalyzers to Reduce Alcohol Use in South Africa

Start date: March 13, 2023
Phase: N/A
Study type: Interventional

This project aims to develop and pilot test an intervention using couple-based motivational interviewing (MI) and mobile breathalyzers to reduce heavy alcohol use with couples living with HIV in South Africa.

NCT ID: NCT05743699 Not yet recruiting - Substance Use Clinical Trials

Adaptation and Evaluation of Bright Horizons

Start date: July 2024
Phase: N/A
Study type: Interventional

This study will test if a program called 'Bright Horizons' is effective at reducing binge substance use among adolescents. Bright Horizons is a culturally adapted intervention developed and tested through a partnership between The White Mountain Apache Tribe and Johns Hopkins University. Bright Horizons is a brief intervention that teaches emotion regulation, coping skills, and problem solving. The intervention also uses goal setting to reduce alcohol and other substance use and to connect to individuals with treatment.

NCT ID: NCT05619185 Recruiting - Clinical trials for Alcohol Use Disorder

A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners

Start date: January 9, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy of an adaptive web intervention (Partners Connect) on military spouse drinking behaviors (CPs) and service member help-seeking (SMs). The investigators want to identify for whom this intervention is most efficacious and on what drinking behaviors and mechanisms. The investigators hypothesize that the intervention will reduce concerned partner drinking and increase service member help-seeking, compared to website resources, and that phone-based CRAFT will increase help-seeking behaviors, compared to those who are guided via a CRAFT workbook.

NCT ID: NCT05560425 Completed - Alcohol Abuse Clinical Trials

Pilot Study on Training Emerging Adults Skills in Navigating College

SINC
Start date: September 11, 2023
Phase: N/A
Study type: Interventional

Lifetime risk for developing an alcohol use disorder increases with earlier onset of alcohol consumption. This risk may reflect a tendency for escalated alcohol intake among youth due to immature executive control, leading to more frequent binge drinking, which is associated with more alcohol-related problems. Binge drinking is associated with deficits in behavioral flexibility, which may suggest impaired control networks that contribute to automatic behavior. Individuals with an alcohol or substance use disorder (A/SUD) exhibit attentional bias toward drug- or alcohol-related stimuli that have attained salience through consistent use. Reward history increases attention towards non-drug stimuli, even among individuals with no lifetime A/SUD. Preliminary data (from Dr. Boettiger's lab) from a nationally representative US adult sample using data collected via Prolific found that a questionnaire measure of mindfulness moderates the relationship between alcohol misuse and attention to reward. Given evidence that heavy alcohol drinking impairs behavioral flexibility, which in turn promotes escalating intake, insight into the relationship between mindfulness and behavioral flexibility could inspire new strategies to prevent alcohol and substance use disorders in people at elevated risk.

NCT ID: NCT05476588 Recruiting - Alcohol Abuse Clinical Trials

Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform

TAPS-ESP
Start date: July 15, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to validate the TAPS-ESP as a screen and assessment that can be used in primary care for the screening and treatment of substance use.